Skip to main content

Table 10 T cell epitope content comparison (EpiCC) analysis

From: A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

Treatment Group (T) and description

EpiCC scores

Percent coverage

% Improvement of homologous vs heterologous coverage a

 

Vaccine

Challenge

PCV2a ORF2 b

PCV2b ORF2 c

PCV2a ORF2 b

PCV2b ORF2 c

T02 homologous treatment

cPCV2a

PCV2a

10.42 d

7.51

100.00

72.05

36.46

T04 heterologous treatment

cPCV2a

PCV2b

7.51

10.25 d

73.28

100.00

  1. a The percent improvement of homologous (cPCV2a vaccine, PCV2a challenge) versus heterologous (cPCV2a vaccine, PCV2b challenge) coverage (|(heterologous-homologous)|/heterologous * 100%) representing the situation in Study A.
  2. b Situation tested in studies A and B.
  3. c Situation tested in study C.
  4. d Represents baseline where the challenge strain is identical to the vaccine strain.